| | |
n
|
Percentage
|
|---|
|
Age: median
| |
51 years
| |
|
Age: range
| |
29–65
| |
|
Menstrual status
|
Pre
|
14
|
52
|
| |
Peri
|
6
|
22
|
| |
Post
|
7
|
26
|
|
Clinical TNM stage at diagnosis
|
T2
|
12
|
44
|
| |
T3
|
13
|
48
|
| |
T4
|
2
|
7
|
|
Clinical node status
|
N0
|
17
|
63
|
| |
N1
|
10
|
37
|
|
Breast
|
Right
|
15
|
56
|
| |
Left
|
12
|
44
|
|
Breast surgery
|
Wide excision
|
12
|
44
|
| |
Mastectomy
|
15
|
56
|
|
Postoperative radiotherapy
|
Nil
|
2
|
7
|
| |
Breast
|
12
|
44
|
| |
Chest wall
|
13
|
48
|
|
ER status (biopsy)
|
ER-positive
|
15
|
56
|
| |
ER-negative
|
12
|
44
|
|
HER-2 status (biopsy)
|
HER-2-positive
|
11
|
41
|
| |
HER-2-negative
|
16
|
59
|
|
Tumour grade
|
Unknown*
|
5
|
19
|
| |
G1
|
2
|
7
|
| |
G2
|
9
|
33
|
| |
G3
|
11
|
41
|
|
Pathological T stage
|
pCR
|
0
|
0
|
| |
pT1
|
8
|
30
|
| |
pT2
|
17
|
63
|
| |
pT3
|
2
|
7
|
|
Pathological N stage
|
pN0
|
11
|
41
|
| |
pN1
|
12
|
44
|
| |
pNX
|
4
|
15
|
- *Grading not possible due to chemotherapy artefact. ER, oestrogen receptor; HER-2, human epidermal growth factor 2; TNM, tumour, node, metastasis.
